AMGEN INC is 113.0x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($182.28 B vs $1.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RXRX | AMGN |
|---|---|---|
| Market cap | $1.61 B | $182.28 B |
| US-listed rank | #2258 | #80 |
| Revenue (latest FY) | $74.68M | $36.75B |
| Net income (latest FY) | -$644.76M | $7.71B |
| Net margin | -863.4% | 21.0% |
| P/E (trailing FY) | - | 23.6 |
| SEC filings | 908 | 1,011 |
AMGEN INC is 113.0x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($182.28 B vs $1.61 B).
In their latest fiscal years, RECURSION PHARMACEUTICALS, INC. reported $74.68M in revenue while AMGEN INC reported $36.75B.
Full pages: RECURSION PHARMACEUTICALS, INC. and AMGEN INC, or browse the full rankings.